 |
New Partnerships Formed To Develop HIV/AIDS Vaccines
The National Institute of Allergy and Infectious Diseases (NIAID) announced
today four novel public-private partnerships to accelerate development of
promising HIV/AIDS vaccines for use around the world. The new partnerships,
called HIV Vaccine Design and Development Teams (HVDDT), tap the different
skills and talents of private industry and academic research centers, and
provide incentive to move strong HIV/AIDS vaccine candidates out of the
laboratory and into human testing.
More...
|
|
 |
HIV Vaccine Glossary
HIV/AIDS vaccines have been in the news as vaccine development teams race to clinical trials on human subjects. To help you cut through the jargon of vaccine development, Vidyya presents this glossary of HIV vaccine terms. More...
|
|
 |
Why An AIDS Vaccine?
Globally, one in every 100 adults 15 to 49 years of age is
HIV-infected; at least 80 percent of these infections are due to heterosexual
transmission. By the end of 1997, an estimated 30.6 million people worldwide were living
with HIV/AIDS, including 1.1 million children younger than 15 years of age. Since the
beginning of the HIV/AIDS epidemic, at least 8.2 million children younger than 15 have
been orphaned because of the premature deaths of HIV-infected parents. More...
|
|
 |
HIV Infection And AIDS
More than 700,000 cases of AIDS have been reported in the United States since 1981, and as many as 900,000 Americans may be infected with HIV. The epidemic is growing most rapidly among minority populations and is a leading killer of African American males. According to the U.S. Centers for Disease Control and Prevention (CDC), AIDS affects six times more African Americans than whites and three times more Hispanics than whites. More... |
|